Thyroid eye disease is a rare chronic condition, and Tepezza® was the first drug approved by the FDA for its treatment in 2020. Patients with rare diseases often have few treatment options available, and the approval of Tepezza® was an important milestone for the treatment of thyroid eye disease.
This medication attaches to proteins found on the surface of cells to keep the immune system from activating the damaging proteins. This protects the affected muscle and fat tissue behind your eyes from your immune system.
Conditions treated by Tepezza®
Though a relatively rare condition, thyroid eye disease can be serious and progressive. In some cases, it can result in vision loss. TED is also known as Graves’ eye disease, Graves’ ophthalmopathy, and Graves’ orbitopathy.
What to expect with infusion therapy of Tepezza®
Your physician will determine the dosage based on your medical condition, weight, and other factors. Tepezza® is usually given as a series of infusions approximately every three weeks for a total of eight doses, which equals a total duration of about five months of treatment.
Injection site reactions may include increased blood pressure, fast heartbeat, headache, or muscle pain. Side effects of Tepezza® can include muscle spasms, fatigue, weakness, nausea, dry skin, or a change in hearing and taste senses. Though temporary hair loss may also occur, growth should return to normal after completed the course of treatment.
It is usually safe and often recommended to use eye drops during your Tepezza® treatment, but we recommend discussing it with your doctor prior to use.
FlexCare has the highest approval rate of second-course Tepezza referrals. Contact us if your second course of treatment was previously denied.
Getting Started With Infusion Therapy
If you have any questions about thyroid eye disease or infusion therapy, contact us directly. We look forward to helping you on your journey to better health.